Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New screening method could catch hidden lung complication early

NCT ID NCT05776225

Knowledge-focused Sponsor: United Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at ways to screen for pulmonary hypertension (high blood pressure in the lungs) in people who already have interstitial lung disease. The goal was to find this complication earlier. 314 adults with various types of lung disease took part in the screening tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

314 people

The number who actually took part.

Started

Aug 2023

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with PH-ILD being treated in any setting, including academic, community, etc.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Patient gives voluntary written informed consent to participate in the study and are capable of reading and understanding questionnaires or forms in English or Spanish. 2. Patients with a diagnosis of ILD based on computed tomography imaging, including: 1. Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis 2. Connective tissue disease-associated ILD with forced vital capacity (FVC) \<70% 3. Hypersensitivity pneumonitis 4. Scleroderma-related ILD 5. Autoimmune ILD 6. Nonspecific interstitial pneumonia 7. Occupational lung disease 8. Combined pulmonary fibrosis and emphysema with mild emphysema on lung imaging as determined by the Investigator 3. Patients must have at least 2 signs or symptoms suggestive of PH, as specified by the study protocol. Exclusion Criteria 1. Prior RHC with mPAP \>20 mmHg. 2. Currently on a Food and Drug Administration (FDA)-approved pulmonary arterial hypertension (PAH) medication for the treatment of PAH. 3. Diagnosed with chronic obstructive pulmonary disease (CPFE with mild emphysema notwithstanding). 4. Uncontrolled or untreated moderate to severe sleep apnea as determined by the patient's physician. 5. Pulmonary embolism within the past 3 months. 6. History of ischemic heart disease or left-sided myocardial dysfunction within 12 months of Screening, defined as left ventricular ejection fraction \<40% or pulmonary capillary wedge pressure \>15 mmHg. 7. Any other clinical features that, in the opinion of the Investigator, might adversely affect interpretation of study data or study safety, or make the patient unsuitable for RHC or HRCT (e.g., pregnancy).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Interstitial lung disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease Pulmonary hypertension

Contacts and locations

Locations

  • AnMed Health Pulmonary and Sleep Medicine

    Anderson, South Carolina, 29621, United States

  • Blessing Health Hannibal

    Hannibal, Missouri, 63401, United States

  • Cleveland Clinic Florida

    Weston, Florida, 33331, United States

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, 03756, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • East Carolina University

    Greenville, North Carolina, 27834, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Hartford Hospital

    Hartford, Connecticut, 06106, United States

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

  • Inova Fairfax Hospital

    Falls Church, Virginia, 22042, United States

  • Intermountain Healthcare

    Murray, Utah, 84107, United States

  • Jersey Shore University Medical Center

    Neptune City, New Jersey, 07753, United States

  • LSU Health Sciences Center New Orleans

    New Orleans, Louisiana, 70112, United States

  • Lakeland Regional Health

    Lakeland, Florida, 33805, United States

  • Legacy Health

    Portland, Oregon, 97210, United States

  • Loyola University Chicago

    Chicago, Illinois, 60153, United States

  • Marshall Health

    Huntington, West Virginia, 25701, United States

  • Mclaren Greater Lansing

    Okemos, Michigan, 48864, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • NCH Healthcare System

    Naples, Florida, 34102, United States

  • NYU Langone Medical Center

    New York, New York, 10016, United States

  • NorthShore University Health System

    Glenview, Illinois, 60025, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Piedmont Healthcare

    Austell, Georgia, 30106, United States

  • Premier Pulmonary Critical Care and Sleep Medicine

    Denison, Texas, 75020, United States

  • Prisma Health

    Columbia, South Carolina, 29203, United States

  • Providence Medical Research Center

    Spokane, Washington, 99204, United States

  • Pulmonary Associates

    Phoenix, Arizona, 85032, United States

  • Pulmonary Associates of Richmond

    Richmond, Virginia, 23229, United States

  • Pulmonix, LLC

    Greensboro, North Carolina, 27403, United States

  • Renown Regional Medical Center

    Reno, Nevada, 89502, United States

  • Sentara Cardiovascular Research Institute

    Norfolk, Virginia, 23507, United States

  • St. Luke's University Health Network

    Bethlehem, Pennsylvania, 18015, United States

  • StatCare Pulmonary Consultants

    Knoxville, Tennessee, 37909, United States

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229, United States

  • The University of Vermont Medical Center

    Burlington, Vermont, 05446, United States

  • University of Kentucky Medical Center

    Lexington, Kentucky, 40536, United States

  • University of Michigan Int Med Pulmonary and Critical Care

    Ann Arbor, Michigan, 48109, United States

  • University of South Florida Health

    Tampa, Florida, 33606, United States

  • University of Utah Health

    Salt Lake City, Utah, 84108, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.